Macrophages in T cell-mediated rejection of renal allografts: pathological mechanisms and CAR-macrophage immunotherapy
9 affiliations
- 1Kidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P.R. China
- 2Institute of Nephropathy, Zhejiang University, Hangzhou, Zhejiang, P.R. China
- 3Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, Zhejiang, P.R. China
- 4Cheeloo College of Medicine, Shandong University, Jinan, Shandong, P.R. China
- 5Department of Nephrology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P.R. China
- 6XiangYa School of Medicine, Central South University, Changsha, Hunan, P.R. China
- 7Department of The Second Clinical School of Medicine, Anhui Medical University, Hefei, Anhui, China
- 8Department of Geriatrics, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P.R. China
- 9Thomas E. Starzl Transplantation Institute/UPMC, University of Pittsburgh, Pittsburgh, PA, USA
Abstract
Acute T cell-mediated rejection (TCMR) remains an important cause of early and intermediate-term graft dysfunction after kidney transplantation. As effector cells that bridge innate and adaptive immunity, macrophages are deeply implicated in the initiation, progression, and fibrotic sequelae of TCMR. This review synthesizes their multifaceted pathological roles: antigen presentation and T cell activation during early rejection, pro-inflammatory polarization driving parenchymal injury, chemokine-mediated recruitment that sustains immune infiltration, and macrophage-to-myofibroblast transition (MMT) underlying interstitial fibrosis in chronic graft deterioration. Because conventional immunosuppression is systemic and incompletely addresses the intragraft immune microenvironment, we further examine chimeric antigen receptor macrophages (CAR-Ms) as an emerging strategy for TCMR intervention. Building on current mechanistic insight, we propose two engineering approaches: targeted-elimination CAR-Ms designed to recognize and clear pathogenic effector immune cells, and tolerance-inducing resident CAR-Ms engineered to suppress inflammation and fibrosis while promoting tolerance. Together, these macrophage-engineering strategies provide a conceptual approach to reshaping the renal allograft immune microenvironment and improving long-term graft survival.
Related
- Immune Dynamics of Pathological Complete Response to Neoadjuvant Immunotherapy in Hepatocellular Carcinoma: Mechanisms, Biomarkers, and Prognostic Implications
- Exercise training inhibits inflammation in adipose tissue via both suppression of macrophage infiltration and acceleration of phenotypic switching from M1 to M2 macrophages in high-fat-diet-induced obese mice
- A narrative review of barrier-matched engineering of macrophages for solid tumor immunotherapy: design logic, translational barriers and clinical outlook
- Disruption of the ARID1A-containing SWI/SNF complex reprograms tumor-associated macrophages and enhances immunotherapy response
- Macrophages and immunometabolism in diminished ovarian reserve: pathological features and therapeutic implications.
BibTeX
@article{he2026macrophages,
title = {{Macrophages in T cell-mediated rejection of renal allografts: pathological mechanisms and CAR-macrophage immunotherapy}},
author = {Guohang He and Jianbo Qing and Guming Chen and Shurui Wang and Zixuan Qu and Xiuyan Yang and Hongfeng Huang and Haifeng Gu and Karim Soliman and Hong Jiang},
journal = {Renal Failure},
year = {2026},
month = nov,
doi = {10.1080/0886022x.2026.2753269},
url = {https://doi.org/10.1080/0886022x.2026.2753269},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Macrophages in T cell-mediated rejection of renal allografts: pathological mechanisms and CAR-macrophage immunotherapy
AU - Guohang He
AU - Jianbo Qing
AU - Guming Chen
AU - Shurui Wang
AU - Zixuan Qu
AU - Xiuyan Yang
AU - Hongfeng Huang
AU - Haifeng Gu
AU - Karim Soliman
AU - Hong Jiang
PY - 2026
DA - 2026/11/04
JO - Renal Failure
DO - 10.1080/0886022x.2026.2753269
UR - https://doi.org/10.1080/0886022x.2026.2753269
AB - Acute T cell-mediated rejection (TCMR) remains an important cause of early and intermediate-term graft dysfunction after kidney transplantation. As effector cells that bridge innate and adaptive immunity, macrophages are deeply implicated in the initiation, progression, and fibrotic sequelae of TCMR. This review synthesizes their multifaceted pathological roles: antigen presentation and T cell activation during early rejection, pro-inflammatory polarization driving parenchymal injury, chemokine-mediated recruitment that sustains immune infiltration, and macrophage-to-myofibroblast transition (MMT) underlying interstitial fibrosis in chronic graft deterioration. Because conventional immunosuppression is systemic and incompletely addresses the intragraft immune microenvironment, we further examine chimeric antigen receptor macrophages (CAR-Ms) as an emerging strategy for TCMR intervention. Building on current mechanistic insight, we propose two engineering approaches: targeted-elimination CAR-Ms designed to recognize and clear pathogenic effector immune cells, and tolerance-inducing resident CAR-Ms engineered to suppress inflammation and fibrosis while promoting tolerance. Together, these macrophage-engineering strategies provide a conceptual approach to reshaping the renal allograft immune microenvironment and improving long-term graft survival.
SN - 0886-022X
SN - 1525-6049
ER -